The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime.